185 related articles for article (PubMed ID: 30962658)
1. Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma.
Meng W; Wang B; Mao W; Wang J; Zhao Y; Li Q; Zhang C; Ma J
Nagoya J Med Sci; 2019 Feb; 81(1):93-102. PubMed ID: 30962658
[TBL] [Abstract][Full Text] [Related]
2. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
Venkannagari S; Fiskus W; Peth K; Atadja P; Hidalgo M; Maitra A; Bhalla KN
Oncotarget; 2012 Nov; 3(11):1416-27. PubMed ID: 23232026
[TBL] [Abstract][Full Text] [Related]
3. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
Rahmani M; Aust MM; Benson EC; Wallace L; Friedberg J; Grant S
Clin Cancer Res; 2014 Sep; 20(18):4849-60. PubMed ID: 25070836
[TBL] [Abstract][Full Text] [Related]
4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
6. PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer.
Chen L; Jin T; Zhu K; Piao Y; Quan T; Quan C; Lin Z
Oncotarget; 2017 Feb; 8(7):11937-11949. PubMed ID: 28060760
[TBL] [Abstract][Full Text] [Related]
7. Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma.
Meng W; Wang B; Mao W; Wang J; Zhao Y; Li Q; Zhang C; Tang Y; Ma J
J Exp Clin Cancer Res; 2018 Oct; 37(1):241. PubMed ID: 30285808
[TBL] [Abstract][Full Text] [Related]
8. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.
Piao J; Chen L; Quan T; Li L; Quan C; Piao Y; Jin T; Lin Z
Oncotarget; 2016 Sep; 7(37):60169-60180. PubMed ID: 27507059
[TBL] [Abstract][Full Text] [Related]
9. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
Chang Z; Shi G; Jin J; Guo H; Guo X; Luo F; Song Y; Jia X
Int J Mol Med; 2013 Jun; 31(6):1449-56. PubMed ID: 23588698
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
Kuger S; Flentje M; Djuzenova CS
Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
[TBL] [Abstract][Full Text] [Related]
11. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.
Chen YH; Wei MF; Wang CW; Lee HW; Pan SL; Gao M; Kuo SH; Cheng AL; Teng CM
Cancer Lett; 2015 Feb; 357(2):582-90. PubMed ID: 25497009
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer.
Ellis L; Ku SY; Ramakrishnan S; Lasorsa E; Azabdaftari G; Godoy A; Pili R
Oncotarget; 2013 Dec; 4(12):2225-36. PubMed ID: 24163230
[TBL] [Abstract][Full Text] [Related]
13. Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cells.
Li J; Wang X; Ma C; Xu S; Xu M; Yang J; Wang R; Xue L
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 34223631
[TBL] [Abstract][Full Text] [Related]
14. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
15. The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma.
Yu CC; Huang SY; Chang SF; Liao KF; Chiu SC
Molecules; 2020 May; 25(10):. PubMed ID: 32466169
[TBL] [Abstract][Full Text] [Related]
16. PI3K Pathway Inhibition with NVP-BEZ235 Hinders Glycolytic Metabolism in Glioblastoma Multiforme Cells.
Udawant S; Litif C; Lopez A; Gunn B; Schuenzel E; Keniry M
Cells; 2021 Nov; 10(11):. PubMed ID: 34831287
[TBL] [Abstract][Full Text] [Related]
17. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
18. NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.
Vazquez N; Lopez A; Cuello V; Persans M; Schuenzel E; Innis-Whitehouse W; Keniry M
Cancer Treat Res Commun; 2021; 27():100340. PubMed ID: 33636591
[TBL] [Abstract][Full Text] [Related]
19. The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk.
Seitz C; Hugle M; Cristofanon S; Tchoghandjian A; Fulda S
Int J Cancer; 2013 Jun; 132(11):2682-93. PubMed ID: 23151917
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux.
Li JR; Cheng CL; Yang CR; Ou YC; Wu MJ; Ko JL
Toxicol Lett; 2013 Jul; 220(3):267-76. PubMed ID: 23651616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]